First-line cemiplimab for locally advanced non-small cell lung cancer: Updated subgroup analyses from EMPOWER-Lung 1 and EMPOWER-Lung 3
dc.authorid | Bondarenko, Igor/0000-0002-7071-2471 | |
dc.authorwosid | Bondarenko, Igor/U-5156-2017 | |
dc.contributor.author | Kalinka, E. | |
dc.contributor.author | Bondarenko, I. | |
dc.contributor.author | Gogishvili, M. | |
dc.contributor.author | Melkadze, T. | |
dc.contributor.author | Baramidze, A. | |
dc.contributor.author | Sezer, A. | |
dc.contributor.author | Makharadze, T. | |
dc.date.accessioned | 2024-05-19T14:51:35Z | |
dc.date.available | 2024-05-19T14:51:35Z | |
dc.date.issued | 2023 | |
dc.department | İstinye Üniversitesi | en_US |
dc.description.abstract | [Abstract Not Available] | en_US |
dc.description.sponsorship | Regeneron Pharmaceuticals, Inc.; Sanofi | en_US |
dc.description.sponsorship | Regeneron Pharmaceuticals, Inc. and Sanofi. | en_US |
dc.identifier.endpage | S106 | en_US |
dc.identifier.issn | 1556-0864 | |
dc.identifier.issn | 1556-1380 | |
dc.identifier.issue | 4 | en_US |
dc.identifier.startpage | S106 | en_US |
dc.identifier.uri | https://hdl.handle.net/20.500.12713/5973 | |
dc.identifier.volume | 18 | en_US |
dc.identifier.wos | WOS:000995007600116 | en_US |
dc.identifier.wosquality | N/A | en_US |
dc.indekslendigikaynak | Web of Science | en_US |
dc.language.iso | en | en_US |
dc.publisher | Elsevier Science Inc | en_US |
dc.relation.ispartof | Journal of Thoracic Oncology | en_US |
dc.relation.publicationcategory | Konferans Öğesi - Uluslararası - Kurum Öğretim Elemanı | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.snmz | 20240519_ka | en_US |
dc.subject | [No Keywords] | en_US |
dc.title | First-line cemiplimab for locally advanced non-small cell lung cancer: Updated subgroup analyses from EMPOWER-Lung 1 and EMPOWER-Lung 3 | en_US |
dc.type | Conference Object | en_US |